{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:37:35Z","timestamp":1791974255016,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.biopha.2025.118154","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T17:59:53Z","timestamp":1748627993000},"page":"118154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dimethylarsenic acid (DMA) is the material basis for the oral arsenic realgar in treatment of leukemia"],"prefix":"10.1016","volume":"188","author":[{"given":"Jingzhuo","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118154_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-030-78311-2_3","article-title":"Acute promyelocytic leukemia: update on risk stratification and treatment practices","volume":"181","author":"Salhotra","year":"2021","journal-title":"Cancer Treat. Res."},{"issue":"6","key":"10.1016\/j.biopha.2025.118154_bib2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.biopha.2025.118154_bib3","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1200\/JCO.20.03096","article-title":"Arsenic combined with all-trans retinoic acid for pediatric acute promyelocytic leukemia: report from the CCLG-APL2016 Protocol study","volume":"39","author":"Zheng","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118154_bib4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.etap.2015.08.030","article-title":"Arsenic cardiotoxicity: an overview","volume":"40","author":"Alamolhodaei","year":"2015","journal-title":"Environ. Toxicol. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2025.118154_bib5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(18)30295-X","article-title":"Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118154_bib6","first-page":"1000","article-title":"Analysis on clinical characteristics and risk factors of differentiation syndrome in acute promyelocytic leukemia patients treated with retinoic acid and arsenic trioxide","volume":"34","author":"Li","year":"2017","journal-title":"J. Guangxi. Med. Univ."},{"issue":"33","key":"10.1016\/j.biopha.2025.118154_bib7","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2013.48.8312","article-title":"Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial","volume":"31","author":"Zhu","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118154_bib8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/ajh.25271","article-title":"Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: interim results of the SCCLG-APL clinical study","volume":"93","author":"Yang","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"22","key":"10.1016\/j.biopha.2025.118154_bib10","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1111\/jcmm.17917","article-title":"Acid ground nano-realgar processed product inhibits breast cancer by inducing mitophagy via the p53\/BNIP3\/NIX pathway","volume":"27","author":"Fang","year":"2023","journal-title":"J. Cell. Mol. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.118154_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3892\/ijo.2022.5447","article-title":"Realgar\u2011induced KRAS mutation lung cancer cell death via KRAS\/Raf\/MAPK mediates ferroptosis","volume":"61","author":"Liu","year":"2022","journal-title":"Int. J. Oncol."},{"issue":"17","key":"10.1016\/j.biopha.2025.118154_bib12","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.18632\/aging.204281","article-title":"Realgar (As4S4), a traditional Chinese medicine, induces acute promyelocytic leukemia cell death via the Bcl-2\/Bax\/Cyt-C\/AIF signaling pathway in vitro","volume":"14","author":"Li","year":"2022","journal-title":"Aging"},{"issue":"7","key":"10.1016\/j.biopha.2025.118154_bib13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019000760","article-title":"The simpler, the better: oral arsenic for acute promyelocytic leukemia","volume":"134","author":"Zhu","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.biopha.2025.118154_bib14","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1073\/pnas.0712365105","article-title":"Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia","volume":"105","author":"Wang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118154_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2018.10.037","article-title":"Study of the accumulation and distribution of arsenic species and association with arsenic toxicity in rats after 30 days of oral realgar administration","volume":"247","author":"Yi","year":"2020","journal-title":"J. Ethnopharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118154_bib16","first-page":"383","article-title":"Effect of arsenic trisulfide on survival of mice bearing acute promyelocytic leukemia ascites","volume":"28","author":"Chen","year":"2015","journal-title":"J. Basic. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118154_bib17","first-page":"197","article-title":"Effects of lipoxin A4 on proliferation and apoptosis of K562 and HL-60 leukemic cells","volume":"32","author":"Zhou","year":"2010","journal-title":"Chin. J. Cell. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118154_bib18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41408-023-00949-w","article-title":"Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group","volume":"13","author":"Huang","year":"2023","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.biopha.2025.118154_bib19","first-page":"204","article-title":"The influence on long-term survey of the patients with acute promyelocytic leukemia treated alternatively with compound huangdai tablets and chemotherapy","volume":"16","author":"Xiang","year":"2003","journal-title":"J. Clin. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118154_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13045-022-01368-3","article-title":"Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia","volume":"15","author":"Ma","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"22","key":"10.1016\/j.biopha.2025.118154_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026144","article-title":"Successful treatment of acute promyelocytic leukemia in a 92-year-old man using all-trans retinoic acid combined with oral arsenic: a case report","volume":"100","author":"Shi","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.biopha.2025.118154_bib22","article-title":"Oral etoposide combined with oral arsenic plus retinoic acid for two cases with newly diagnosed high-risk acute promyelocytic leukemia during COVID19 pandemic","volume":"16","author":"Lu","year":"2021","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.biopha.2025.118154_bib23","doi-asserted-by":"crossref","unstructured":"J. Tian, Y. Song, G. Zhang, S. Wang, X. Chu, Y. Chai, et al., Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes, J. Cancer. Res. Clin. Oncol. 150(4) (2024) 189. doi:10.1007\/s00432-024-05700-x.","DOI":"10.1007\/s00432-024-05700-x"},{"key":"10.1016\/j.biopha.2025.118154_bib24","unstructured":"The Coorperatoin group of phase II clinical trial of compound huangdai tablet, Phase II clinical trail of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia, Chin. J. Hematol. 27 (12), 2006. pp. 801\u2013804.."},{"key":"10.1016\/j.biopha.2025.118154_bib25","article-title":"Oral realgar-indigo Naturalis formula plus retinoic acid for acute promyelocytic leukemia","volume":"2021","author":"Lou","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118154_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic. Clin. Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2025.118154_bib27","first-page":"3345","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells","volume":"89","author":"Chen","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biopha.2025.118154_bib28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/mmr.2022.12913","article-title":"Sodium arsenite and dimethylarsenic acid induces apoptosis in OC3 oral cavity cancer cell","volume":"27","author":"Wu","year":"2023","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.118154_bib29","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1002\/cam4.5068","article-title":"Arsenic compounds activate MAPK and inhibit Akt pathways to induce apoptosis in MA-10 mouse Leydig tumor cells","volume":"12","author":"Juan","year":"2023","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118154_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1039\/C4MT00263F","article-title":"The combination of arsenic and cryptotanshinone induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in breast cancer cells","volume":"7","author":"Zhang","year":"2015","journal-title":"Metallomics"},{"issue":"7","key":"10.1016\/j.biopha.2025.118154_bib31","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/14712598.2021.1825678","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults","volume":"21","author":"Goldenson","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2025.118154_bib32","unstructured":"WHO, Environment health criteria 224, arsenic and arsenic compounds, \u3008http:\/\/www.who.int\u3009; 2020 [accessed 15 December 2020]."},{"issue":"14","key":"10.1016\/j.biopha.2025.118154_bib33","first-page":"1889","article-title":"Toxicity study of realgar, China","volume":"36","author":"Liang","year":"2011","journal-title":"J. Chin. Mat. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:54:25Z","timestamp":1758124465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225003488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"alternative-id":["S0753332225003488"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118154","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dimethylarsenic acid (DMA) is the material basis for the oral arsenic realgar in treatment of leukemia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118154"}}